Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from VRTX

Are Wall Street Analysts Predicting Vertex Pharmaceuticals Stock Will Climb or Sink?

Vertex Pharmaceuticals has lagged behind the broader market over the past year, and Wall Street analysts are cautiously optimistic about the stock’s future.

Barchart

3 Genomic Stocks at the Forefront of Precision Medicine

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector continues to evolve, investing in genomic stocks like Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Illumina (ILMN) could be beneficial. Read on….

StockNews.com

3 Biotech Stocks Revolutionizing Healthcare

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth. Thus, investing in fundamentally stable stocks, Vertex Pharmaceuticals (VRTX), Amgen (AMGN), and Gilead Sciences (GILD), could be a wise way to capitalize on the industry’s growing momentum. Read more….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Vertex Pharmaceuticals Earnings Preview: What to Expect

With Vertex Pharmaceuticals gearing up to release its fourth-quarter earnings next month, analysts predict a single-digit drop in profit.

Barchart

3 Biotech Innovators Advancing Genetic Therapies

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global regulations. Considering the advancements, fundamentally solid biotech stocks Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN) are emerging as top choices for investors seeking transformative opportunities. Read further….

StockNews.com

3 Biotech Stocks With Promising Pipelines

The biotech sector’s AI-driven advancements, personalized medicine demand, and streamlined regulations fuel significant market growth. Hence, investors should consider robust biotech stocks such as Vertex Pharmaceuticals (VRTX), Amgen (AMGN), and Gilead Sciences (GILD). Read on.

StockNews.com

Is Vertex Pharmaceuticals Stock Underperforming the Dow?

Despite Vertex Pharmaceuticals’ recent underperformance compared to the Dow Jones, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Is Wall Street Bullish or Bearish on Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart

3 Pharma Stocks to Watch as Gene Therapy Gains Momentum

The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and improve treatment options. Given this favorable trend, it could be wise to watch strong pharma stocks such as Vertex Pharmaceuticals (VRTX), Wave Life Sciences (WVE), and Poseida Therapeutics (PSTX). Read more.

StockNews.com

What You Need to Know Ahead of Vertex Pharmaceuticals' Earnings Release

Vertex Pharmaceuticals will unveil its Q3 earnings next month, and analysts project a lower-single-digit bottom-line growth.

Barchart

Is Vertex Pharmaceuticals Stock Outperforming the Nasdaq?

Vertex Pharmaceuticals has outperformed the Nasdaq over the past year, and analysts remain moderately bullish about the stock's prospects.

Barchart

Are Wall Street Analysts Bullish on Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals has outperformed the broader market in 2024 but Wall Street analysts remain cautiously bullish about the stock's potential.

Barchart

3 Gene-Editing Stocks to Buy for Future Health Advances

With ever-expanding operations and rapid technological innovations, the gene-editing industry looks poised for solid long-term growth. Thus, investors could consider solid stocks Eli Lilly (LLY), Sanofi (SNY), and Vertex Pharmaceuticals (VRTX). Continue reading.

StockNews.com

3 Biotech Stocks With Revolutionary Pipelines to Buy Today

The biotech industry is experiencing rapid growth owing to new drug innovations and advancements in healthcare. To capitalize on the industry's expansion, it could be wise to invest in solid biotech stocks, Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD), which have revolutionary pipelines. Read on….

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

What to Expect From Vertex Pharmaceuticals’ Next Quarterly Earnings Report

Vertex Pharmaceuticals will unveil its Q2 earnings next month, and analysts project a single-digit bottom-line growth.

Barchart

Is Vertex Stock Outperforming the S&P 500?

Vertex has outperformed the S&P 500 over the past year, and analysts are moderately bullish on the stock.

StockNews.com

The biotech industry is poised for significant growth due to the rising orphan drug formulations and the surging popularity of plant-based products. Hence, quality biotech stocks, Exelixis (EXEL), Vertex Pharmaceuticals (VRTX), and Jazz Pharmaceuticals (JAZZ) could be ideal investments for solid returns. Read more….

Investors Business Daily

S&P 500 Giants Lead Five Healthy Stocks Near Buy Points

Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Vertex Pharmaceuticals (VRTX) Earnings Review: Is it Time to Buy?

After a solid first-quarter earnings report, Vertex Pharmaceuticals (VRTX) comfortably topped analysts’ earnings and revenue estimates in the first quarter. But should investors consider adding the stock to their portfolio now? Let’s look at its financial metrics to gauge its prospects….

StockNews.com

3 Biotech Stocks to Invest In Right Now for Long-Term Gains

With the rapidly growing demand for personalized medicine, innovative solutions, and recent developments like AI in drug discovery, the biotech industry's prospects appear robust. Thus, quality biotech stocks Vertex Pharmaceuticals (VRTX), SIGA Technologies (SIGA), and Gilead Sciences (GILD) could be ideal candidates to buy now. Read more….

StockNews.com

Top Biotech 3 Stocks With Accelerating Profits

The biotechnology industry is booming thanks to growing demand for innovative healthcare solutions, favorable government initiatives, and several scientific breakthroughs. Thus, quality biotech stocks Genmab (GMAB), Halozyme Therapeutics (HALO), and Vertex Pharmaceuticals (VRTX) could be ideal buys for substantial profits. Read more….

StockNews.com

Jumpstart Your Portfolio With These 3 Biotech Stocks

The biotech industry’s robust growth potential is fueled by scientific advancements, rapid technological adoption, and supportive government initiatives. Thus, you could consider investing in top biotech stocks Exelixis (EXEL), Vertex Pharmaceuticals (VRTX), and Vanda Pharmaceuticals (VNDA) to strengthen your portfolio. Keep reading….

Investors Business Daily

Three S&P 500 Giants Lead This List Of Stocks Near Buy Points

S&P 500 stocks Lennar, Vertex Pharmaceuticals and Royal Caribbean lead this list of five stocks trading around buy points.

Investors Business Daily

Here's Why IBD Stock Of The Day Vertex Pharmaceuticals Is Newly Actionable

Vertex is the IBD Stock Of The Day. VRTX stock bounced off its 50-day line as investors watch for the first sales of its gene-editing drug.

Barchart

This Could Be the Next Blockbuster Drug Stock to Buy

Vertex Pharmaceuticals just released data from its experimental drug to relieve pain, with no risk of addiction and very few side effects. This opioid alternative could give Vertex - already a powerhouse in the cystic fibrosis segment - another blockbuster drug to add to its portfolio.

1 2 3 4 5

People

Kritika SarmahHer

727 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Vertex Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.